Haloperidol
Research News and Information

Saturday, November 21, 2009

GPR37 surface expression enhancement via N-terminal truncation or protein-protein interactions.

Nov 2009 GPR37, also known as the parkin-associated endothelin-like receptor (Pael-R), is an orphan G-protein-coupled receptor (GPCR) that exhibits poor plasma membrane expression when expressed in most cell types. We sought to find ways to enhance GPR37 ... Read more...

Combination of electroconvulsive therapy with skin graft surgery for a schizophrenic patient with burns.

30 Aug 2009 We report on the use of electroconvulsive therapy (ECT) on a patient with schizophrenia immediately after skin graft surgery for extensive burns. The patient was 22 years old and had been burned in more than 33% of his body because of a suicide ... Read more...

Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.

30 Aug 2009 To compare the effectiveness of a switch from haloperidol (N=99), olanzapine (N=82), or risperidone (N=104) to 12 weeks of treatment with 80-160 mg/day ziprasidone in patients with stable schizophrenia or schizoaffective disorder. Stable outpatients ... Read more...

Latest indexed articles for 'Haloperidol'

These are the very latest articles for this heading:

• GPR37 surface expression enhancement via N-terminal truncation or protein-protein interactions. Nov 2009
• Combination of electroconvulsive therapy with skin graft surgery for a schizophrenic patient with burns. 30 Aug 2009
• Fatal pulmonary embolism following antipsychotic treatment and physical restraint. 30 Aug 2009
• Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. 30 Aug 2009
• Neocortical movement representations are reduced and reorganized following bilateral intrastriatal 6-hydroxydopamine infusion and dopamine type-2 receptor antagonism. 20 Aug 2009
• In vivo evidence that constitutive activity of serotonin2C receptors in the medial prefrontal cortex participates in the control of dopamine release in the rat nucleus accumbens: differential effects of inverse agonist versus antagonist. 20 Aug 2009
• Chorea associated with gabapentin use in an elderly man. 30 Jul 2009
• Intramuscular haloperidol versus intramuscular olanzapine for treatment of acute agitation: a cost-minimization study. 30 Jul 2009
• Examination of reinforcement magnitude on the pharmacological disruption of fixed-ratio performance. 30 Jul 2009
• Effects of yokukansan, a traditional Japanese medicine, on aggressiveness induced by intracerebroventricular injection of amyloid beta protein into mice. 30 Jul 2009
• Nausea and vomiting after office-based anesthesia. 30 Jul 2009
• Long-term ventilatory adaptation and ventilatory response to hypoxia in plateau pika (Ochotona curzoniae): role of nNOS and dopamine. 27 Jul 2009
• Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy. 12 Jul 2009
• Haloperidol plus promethazine for psychosis-induced aggression. 6 Jul 2009
• [Efficacy of clonidine transdermal patch for treatment of Tourette's syndrome in children] 29 Jun 2009
• Antipsychotic treatment alters protein expression associated with presynaptic function and nervous system development in rat frontal cortex. 29 Jun 2009
• Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population. 29 Jun 2009
• Validation of derivative spectrophotometry method for determination of active ingredients from neuroleptics in pharmaceutical preparations. 29 Jun 2009
• Righting elicited by novel or familiar auditory or vestibular stimulation in the haloperidol-treated rat: rat posturography as a model to study anticipatory motor control. 22 Jun 2009
• Targeting pain-depressed behaviors in preclinical assays of pain and analgesia: drug effects on acetic acid-depressed locomotor activity in ICR mice. 22 Jun 2009

See a longer list of these articles.

Technical information about 'Haloperidol'

Definition: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in MENTAL RETARDATION and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)

Chemical name: 1-Butanone, 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-

Registry Number: 52-86-8

Descriptor UI: D006220

Alternative terms: Haloperidol; Haldol;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Antiemetics; Antipsychotic Agents; Dopamine Antagonists; Anti-Dyskinesia Agents;

Tree Number: D02.522.352.506;